title: Endothelin B receptor gene hypermethylation in prostate adenocarcinoma.
abstract: BACKGROUND
  Alterations in the methylation patterns of promoter CpG islands have been associated with the transcriptional inhibition of genes in many human cancers. These epigenetic alterations could be used as molecular markers for the early detection of cancer-that is, while potentially curable according to current therapeutic strategies. In prostate cancer, GSTP1 hypermethylation is the most common epigenetic alteration, and can be detected in up to 90% of cases. Thus, screening for methylation of other loci would probably increase the number of primary tumours amenable to screening. Moreover, previous studies have shown that the endothelin B receptor (EDNRB) gene is abnormally methylated in a high proportion of prostate tumours ( approximately 70%).
  
  
  OBJECTIVE
  To investigate the potential use of EDNRB gene hypermethylation as a prostate cancer specific marker.
  
  
  METHODS
  Methylation specific polymerase chain reaction (MSP) for the promoter region of EDNRB was performed on prospectively collected tissue samples from 48 patients harbouring clinically localised prostate cancer, and in a group of 23 patients with benign prostatic hyperplasia (BPH). Genomic DNA was isolated from the samples and the methylation status was examined in a blinded manner.
  
  
  RESULTS
  EDNRB methylation was found in 40 of 48 of the adenocarcinomas. However, the same alteration was found in the paired normal tissue, and 21 of 23 of the BPH samples were found to harbour EDNRB hypermethylation.
  
  
  CONCLUSIONS
  EDNRB hypermethylation at CpG sites upstream of the transcription start site can be detected in a high proportion of prostate adenocarcinomas. However, because this same alteration is also present in normal and hyperplastic tissue, it does not distinguish normal from neoplastic prostate cells, thus precluding its use as a prostate cancer marker.
authors.affiliation: Portuguese Oncology Institute, R. Dr. Antonio Bernardino de Almeida, 4200-072 Porto, Portugal. cjeronimo@hotmail.com
authors.forename: C
authors.initials: C
authors.lastname: Jerónimo
authors.forename: R
authors.initials: R
authors.lastname: Henrique
authors.forename: P F
authors.initials: PF
authors.lastname: Campos
authors.forename: J
authors.initials: J
authors.lastname: Oliveira
authors.forename: O L
authors.initials: OL
authors.lastname: Caballero
authors.forename: C
authors.initials: C
authors.lastname: Lopes
authors.forename: D
authors.initials: D
authors.lastname: Sidransky
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics*; D000368:Aged; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics; D005819:Genetic Markers; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics*; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; D005819:Genetic Markers; D009363:Neoplasm Proteins; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin